<DOC>
	<DOCNO>NCT00006345</DOCNO>
	<brief_summary>RATIONALE : Denileukin diftitox may able deliver cancer-killing substance directly T-cell lymphoma cell . Dexamethasone may decrease side effect denileukin diftitox . PURPOSE : Phase II trial study effectiveness dexamethasone prevent side effect follow treatment denileukin diftitox treat patient persistent recurrent T-cell lymphoma .</brief_summary>
	<brief_title>Dexamethasone Followed Denileukin Diftitox Treating Patients With Persistent Recurrent T-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate potential benefit dexamethasone administer prior denileukin diftitox term avoidance and/or reduction hypersensitivity type reaction , flu-like symptom complex , vascular leak syndrome side effect ( adverse event ) patient persistent recurrent cutaneous T-cell lymphoma . II . Assess response rate term tumor burden reduction patient treat regimen . III . Determine rate patient withdrawal study due adverse effect . OUTLINE : This open label , multicenter study . Patients receive denileukin diftitox IV 30-60 minute day 1-5 . Patients also receive oral dexamethasone twice daily begin 24 hour prior concomitantly denileukin diftitox . Treatment continue every 3 week least 6 course absence disease progression unacceptable toxicity . Patients follow 2 4 week . PROJECTED ACCRUAL : Approximately 15-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis persistent recurrent cutaneous Tcell lymphoma ( CTCL ) suitable denileukin diftitox therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Albumin least 3.0 mg/dL Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 28 day prior study No known hypersensitivity denileukin diftitox component ( e.g. , diphtheria toxin , interleukin2 , excipients ) dexamethasone No concurrent serious , uncontrolled infection would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior denileukin diftitox ( DAB389interleukin2 ) DAB486interleukin2 No concurrent interferon Chemotherapy : No concurrent chemotherapy* No concurrent extracorporeal photochemotherapy* No concurrent systemic combination cytotoxic chemotherapy No concurrent topical chemotherapy *For remission induction CTCL Endocrine therapy : No concurrent corticosteroid Radiotherapy : No concurrent electron beam radiotherapy and/or photophoresis Surgery : Not specify Other : At least 21 day since prior anticancer therapy recover No concurrent anticancer therapy CTCL No concurrent experimental drug approve drug test investigational setting No concurrent topical therapy* No concurrent phototherapy* No concurrent cyclosporine No concurrent systemic retinoids *For remission induction CTCL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2001</verification_date>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
</DOC>